ABSTRACT
Electroluminescence (EL) from the singlet-excited (S1) state is the ideal choice for stable, high-performing deep-blue organic light-emitting diodes (OLEDs) owing to the advantages of an adequately short radiative lifetime, improved device durability, and low cost, which are the most important criteria for their commercialization. Herein, we present the design and synthesis of three donor-acceptor-donor (D-A-D)-configured deep-blue fluorescent materials (denoted as TC-1, TC-2, and TC-3) composed of a thioxanthone or diphenyl sulfonyl acceptor and phenyl carbazolyl donor. These systems exhibit strong deep-blue photoluminescence (422-432 nm) in solutions and redshifted emission (472-486 nm) in thin films. The solid-state photoluminescence quantum yield (PLQY) was estimated to be 78 and 94% for TC-2 and TC-3, respectively. TC-2 and TC-3 possess good molecular packing and large molecular cross-sectional areas, which not only improves the PLQY but enhances the triplet-triplet annihilation up-conversion (TTAUC) efficiency of fluorescent emitters. Furthermore, both compounds were applied as an acceptor for confirming their TTAUC property using bis(2-methyldibenzo[f,h]quinoxaline)(acetylacetonate)iridium(III) (Ir(MDQ)2acac) as the sensitizer. Non-doped OLEDs based on TC-2 and TC-3 exhibit blue EL in the 461-476 nm range. In particular, TC-3 exhibits a maximum external quantum efficiency (EQEmax) of 5.1%, and its EL maximum is 476 nm. In addition, the three emitters were employed as hosts in red OLEDs using bis(1-phenylisoquinoline)(acetylacetonate)iridium(III) (Ir(piq)2acac) as the phosphorescent dopant. The red phosphorescent OLEDs based on TC-1, TC-2, and TC-3 achieve excellent EQEmax values of 21.6, 22.9, and 21.9%, respectively, and peak luminance efficiencies of 12.0, 14.0, and 12.3 cd A-1. These results highlight these fluorophores' versatility and promising prospects in practical OLED applications.
ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: With the features of multiple-components and targets as well as multifunction, traditional Chinese medicine (TCM) has been widely used in the prevention and treatment of various diseases for a long time. During the application of TCM, the researches about bioavailability enhancement of the bioactive constituents in formula are flourishing. Bushen-Yizhi formula (BSYZ), a TCM prescription with osthole (OST) as one of the main bioactive ingredients, have been widely used to treat kidney deficiency, mental retardation and Alzheimer's disease. However, the underlying biological mechanism and compound-enzyme interaction mediated bioavailability enhancement of OST are still not clearly illuminated. AIM OF THE STUDY: The aim of this study is to explore the material basis and molecular mechanism from BSYZ in the bioavailability enhancement of OST. Screening the potential CYP3A4 inhibitors using theoretical prediction and then verifying them in vitro, and pharmacokinetics study of OST in rat plasma under co-administrated of screened CYP3A4 inhibitors and BSYZ were also scarcely reported. MATERIALS AND METHODS: Screening of CYP3A4 inhibitors from BSYZ was performed with molecular docking simulation from systems pharmacology database. The screened compounds were verified by using P450-Glo Screening Systems. A multiple reaction monitoring (MRM) mass spectrometry method was established for OST quantification. Male Sprague-Dawley rats divided into four groups and six rats in each group were employed in the pharmacokinetics study of OST. The administrated conditions were group I, OST (20 mg/kg); group II, BSYZ (containing OST 1 mg/mL, at the dose of 20 mg/kg OST in BSYZ); group III, co-administration of ketoconazole (Ket, 75 mg/kg) and OST (20 mg/kg); group IV, co-administration of CYP3A4 inhibitor (10 mg/kg) and OST (20 mg/kg). They were determined by using HPLC-MS/MS (MRM) and statistical analysis was performed using student's t-test with p < 0.05 as the level of significance. RESULTS: 21 potential CYP3A4 inhibitors were screened from BSYZ compounds library. From the results of verification in vitro, we found 4 compounds with better CYP3A4 inhibition efficiency including Oleic acid, 1,2,3,4,6-O-Pentagalloylglucose, Rutin, and Schisantherin B. Under further verification, Schisantherin B exhibited the best inhibitory effect on CYP3A4 (IC50 = 0.339 µM), and even better than the clinically used drug (Ket) at the concentration of 5 µM. In the study of pharmacokinetics, the area under the curve (AUC, ng/L*h) of OST after oral administration of BSYZ, Ket and Schisantherin B (2196.23 ± 581.33, 462.90 ± 92.30 and 1053.03 ± 263.62, respectively) were significantly higher than that of pure OST treatment (227.89 ± 107.90, p < 0.01). CONCLUSIONS: Schisantherin B, a profoundly effective CYP3A4 inhibitor screened from BSYZ antagonized the metabolism of CYP3A4 on OST via activity inhibition, therefore significantly enhanced the bioavailability of OST in rat plasma. The results of this study will be helpful to explain the rationality of the compatibility in TCM formula, and also to develop new TCM formula with more reasonable drug compatibility.
